Inhibition of the B cell associated tyrosine kinase SYK as a potential therapeutic target in aggressive lymphomas.

被引：0
|
作者：
Bertoni, F
Ridaidi, A
Sasso, A
Uccella, S
Martin, V
Napoli, S
Pruneri, G
Zucca, E
Capella, C
Catapano, CV
Tibiletti, MG
Cavalli, F
机构：
[1] Oncol Inst Sos Switzerland, Expt Oncol Lab, Bellinzona, Switzerland
[2] Oncol Inst Sos Switzerland, Lymphoma Unit, Bellinzona, Switzerland
[3] Univ Insubria, Osped Circolo, Anat Pathol Unit, Varese, Italy
[4] European Inst Oncol, Div Pathol & Lab Med, Milan, Italy
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1469
引用
收藏
页码：424A / 424A
页数：1
相关论文
共 50 条
  • [31] Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth
    Gururajan, Murali
    Dasu, Trivikram
    Shahidain, Seif
    Jennings, C. Darrell
    Robertson, Darrell A.
    Rangnekar, Vivek M.
    Bondada, Subbarao
    JOURNAL OF IMMUNOLOGY, 2007, 178 (01): : 111 - 121
  • [32] An Orally Available Syk Tyrosine Kinase Inhibitor Induces Apoptosis in Peripheral T-Cell Lymphomas Overexpressing Activated Syk
    Wilcox, R.
    Sun, D.
    Remstein, E. D.
    Dogan, A.
    Ansell, S.
    Feldman, A. L.
    MODERN PATHOLOGY, 2009, 22 : 291A - 291A
  • [33] An Orally Available Syk Tyrosine Kinase Inhibitor Induces Apoptosis in Peripheral T-Cell Lymphomas Overexpressing Activated Syk
    Wilcox, R.
    Sun, D.
    Remstein, E. D.
    Dogan, A.
    Ansell, S.
    Feldman, A. L.
    LABORATORY INVESTIGATION, 2009, 89 : 291A - 291A
  • [34] Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas
    Bi, Chengfeng
    Zhang, Xuan
    Lu, Ting
    Zhang, Xiaoyan
    Wang, Xianhuo
    Meng, Bin
    Zhang, Huilai
    Wang, Ping
    Vose, Julie M.
    Chan, Wing C.
    McKeithan, Timothy W.
    Fu, Kai
    HAEMATOLOGICA, 2017, 102 (04) : 755 - 764
  • [35] Different patterns of genetic aberrations in nodal and primary extranodal aggressive B-cell lymphomas.
    Viardot, A
    Baudis, M
    Möller, P
    Barth, TFE
    Feller, AC
    Ott, G
    Trümper, L
    Lichter, P
    Döhner, H
    Bentz, M
    BLOOD, 1999, 94 (10) : 517A - 517A
  • [36] SYK TYROSINE KINASE REQUIRED FOR MOUSE VIABILITY AND B-CELL DEVELOPMENT
    CHENG, AM
    ROWLEY, B
    PAO, W
    HAYDAY, A
    BOLEN, JB
    PAWSON, T
    NATURE, 1995, 378 (6554) : 303 - 306
  • [37] The SYK tyrosine kinase is essential for B cell antigen receptor signaling.
    Matsuuchi, L
    Richards, J
    Gold, MR
    DeFranco, AL
    Hourihane, SL
    FASEB JOURNAL, 1996, 10 (06): : 382 - 382
  • [38] B cell development requires the tyrosine kinase Syk at two distinct checkpoints
    Turner, M
    Walters, AE
    Quinn, ME
    Tybulewicz, VLJ
    IMMUNOLOGY, 1996, 89 : AA405 - AA405
  • [39] Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway
    Yu Yu
    Yohan Suryo Rahmanto
    Meng-Horng Lee
    Pei-Hsun Wu
    Jude M. Phillip
    Chuan-Hsiang Huang
    Michele I. Vitolo
    Stephanie Gaillard
    Stuart S. Martin
    Denis Wirtz
    Ie-Ming Shih
    Tian-Li Wang
    Oncogene, 2018, 37 : 3778 - 3789
  • [40] Current diagnostic and therapeutic standards in aggressive B-cell lymphomas
    Friedrichs, Birte
    Schmitz, Norbert
    Lenz, Georg
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2020, 145 (03) : 151 - 154
12345